Clarkston Capital Partners LLC Invests $897,000 in Zoetis Inc. $ZTS

Clarkston Capital Partners LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 7,584 shares of the company’s stock, valued at approximately $897,000.

A number of other institutional investors have also made changes to their positions in ZTS. Prosperity Bancshares Inc acquired a new position in shares of Zoetis during the fourth quarter valued at $25,000. Cassaday & Co Wealth Management LLC bought a new position in Zoetis in the first quarter valued at about $28,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis in the fourth quarter worth about $30,000. Elyxium Wealth LLC acquired a new stake in Zoetis in the fourth quarter worth about $32,000. Finally, Root Financial Partners LLC raised its holdings in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus reduced their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. UBS Group reduced their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Barclays decreased their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Finally, Morgan Stanley cut their price target on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating on the stock in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $119.50.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 11,650 shares of company stock valued at $886,384 in the last quarter. Company insiders own 0.22% of the company’s stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union, a first-in-class long-acting anti-NGF treatment for cat osteoarthritis pain. The launch supports new international revenue growth and highlights the company’s innovation pipeline. Article title
• Neutral Sentiment: An investor letter highlighted Zoetis as a possible entry point, arguing that temporary concerns may be creating an opportunity. This is supportive sentiment, but it is opinion-based rather than a company-specific catalyst. Article title
• Negative Sentiment: Multiple law firms announced or reminded investors about a securities class action lawsuit against Zoetis, with a July 27 lead-plaintiff deadline. The repeated legal notices may pressure sentiment by keeping alleged investor-harm concerns in focus. Article title

Zoetis Stock Up 0.5%

Shares of ZTS stock opened at $74.53 on Friday. The firm’s fifty day moving average price is $77.26 and its two-hundred day moving average price is $104.46. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $160.48. The firm has a market capitalization of $31.25 billion, a P/E ratio of 12.36, a PEG ratio of 1.16 and a beta of 0.75.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 earnings per share. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.8%. Zoetis’s payout ratio is 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.